Prostate Cancer Prevention by Sulforaphane, a Novel Dietary Histone Deacetylase Inhibitor
Annual rept. 1 Jan 2007-31 Dec 2008
OREGON STATE UNIV CORVALLIS
Pagination or Media Count:
Prostate cancer is the second leading cause of cancer related death in men. To test Sulforaphane SFN as a novel histone deacetylases HDAC inhibitor and explore the mechanism of SFN protection against prostate cancer, normal prostate cells and different stage of prostate cancerous cells were treated with 15M SFN and harvest to test cell viability, cell cycle arrest, apoptosis, HDAC activity, transcription and protein level of HDACs and tumor suppressor genes. MTT cell viability showed that SFN inhibited prostate cancerous cell growth only. SFN also inhibited HDAC activity in prostate cancerous cell alone but not normal cells. SFN selectively induced cell cycle arrest and apoptosis in prostate cancer cells, but not normal prostate cells. SFN increased mRNA and protein level of tumor suppressor gene p21 in prostate cancerous cells. All the study showed that SFN is a HDAC inhibitor and protected against cancer development through epigenetic alteration in prostate cancer cells.
- Medicine and Medical Research